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Abstract
Percutaneous treatment (PT) emerged in the mid-1980s as an alternative to surgery for selected cases of abdominal cystic
echinococcosis (CE). Despite its efficacy and widespread use, the puncture of echinococcal cysts is still far from being
universally accepted. One of the main reasons for this reluctance is the perceived risk of anaphylaxis linked to PTs. To
quantify the risk of anaphylactic reactions and lethal anaphylaxis with PT, we systematically searched MEDLINE for
publications on PT of CE and reviewed the PT-related complications. After including 124 publications published between
1980 and 2010, we collected a total number of 5943 PT procedures on 5517 hepatic and non-hepatic echinococcal cysts.
Overall, two cases of lethal anaphylaxis and 99 reversible anaphylactic reactions were reported. Lethal anaphylaxis occurred
in 0.03% of PT procedures, corresponding to 0.04% of treated cysts, while reversible allergic reactions complicated 1.7% of
PTs, corresponding to 1.8% of treated echinococcal cysts. Analysis of the literature shows that lethal anaphylaxis related to
percutaneous treatment of CE is an extremely rare event and is observed no more frequently than drug-related anaphylactic
side effects.
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Introduction
Human cystic echinococcosis (CE), caused by the larval stage of
the cestode Echinococcus granulosus, is a cosmopolitan parasitic
zoonosis, affecting mainly the liver (,70%) and the lung (,20%)
of the human intermediate host. Clinical symptoms depend on the
location, number, and size of the cysts. Until anthelminthic
chemotherapy became available (mebendazole in the 1970s and
albendazole in the early 1980s), surgery was the only treatment
choice. The spectrum of therapeutic options was further extended
in the mid-1980s when the increasing availability of modern
imaging techniques, namely ultrasound, allowed the introduction
of image-guided percutaneous treatment (PT) methods.
Over the years, various PTs have been developed, based on the
classic PAIR (Puncture of the cyst, Aspiration of the cyst fluid,
Injection of a scolicidal agent, and Re-aspiration of the cyst
content) procedure [1,2] with minor variations of the essential
steps [3–5]. Different catheterization techniques allowing aspira-
tion of the solid content of cysts have also been developed for those
cyst stages that are often unresponsive to PAIR [6,7].
Despite the wide use of PTs in the last two and a half decades,
the fear of anaphylactic shock and dissemination due to the
spillage of cystic fluid is still quoted by physicians favoring surgery
for the treatment of CE [8,9]. However, anaphylactic reactions in
CE occur not only as a side effect of PT, but also of surgical
treatment [10–17], result of accidental trauma [18–20] and even
spontaneously [21–24].
To our knowledge there are no updated figures on the frequency
of anaphylactic reactions, anaphylactic shock or lethal anaphylaxis
following PTs of echinococcal cysts. To quantify the risk of allergic
reactions and lethal anaphylaxis related to PT of echinococcal cysts
we systematically reviewed the published literature.
Methods
We performed a PubMed (MEDLINE) search of the literature
using the key words ‘‘echinococcal cysts’’, ‘‘hydatid cysts’’, ‘‘cystic
echinococcosis’’, ‘‘hydatidosis’’, ‘‘PAIR’’, and ‘‘percutaneous treat-
ment’’ and reviewed the available references published between
January 1980 and December 2009 for eligible publications
(Figure 1).
The inclusion criteria were as follows:
All publications on PT of E. granulosus cysts with information
about the number of treated cysts, the number of PT procedures
and the occurrence of lethal complications were included. When
the original article was not obtainable but the abstract containing
the requested information was, the publication was included in the
analysis.
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In some cases repeated PTs of the same echinococcal cysts were
performed during the course of treatment. In these instances, we
collected the total number of treated echinococcal cysts and the
corresponding total number of PT procedures.
To avoid multiple counting (duplication) of identical procedures
and cases, follow-up publications on identical procedures and cases
were traced and excluded (references S1).
In human CE, the liver is the organ most frequently affected.
Therefore, we divided the collected cases and PT procedures
according to the anatomical location into ‘‘hepatic cysts’’ (Table
S1) and ‘‘extra-hepatic cysts’’ (Table S2).
When the exact anatomical locations of the cysts were not
specified, the data was collected separately (Table 1).
Information about the reported complications was collected
accordingly, differentiated into ‘‘lethal complications’’ and ‘‘re-
versible complications’’ and summarized (Tables 2, 3, 4, 5, 6, 7).
It was impossible to retrospectively grade the severity of the
reversible anaphylactic reactions due to the lack of a standardized
definition of the events.
If the authors labelled subjective severity levels of the observed
anaphylactic reactions (e.g. ‘‘severe’’, ‘‘moderate’’, ‘‘mild’’,
‘‘minor’’) we collected, summarized and listed them accordingly.
In addition to the evaluation and quantification of anaphylactic
reactions, we also collected and summarized other PT related
complications, to allow a representative overview of all PT
relevant complications.
Results
One hundred-twenty-four publications met our inclusion
criteria, with a total number of 5943 PT procedures performed
for the diagnosis or treatment of 5517 echinococcal cysts. Ninety-
two publications that did not meet the inclusion criteria were
excluded from the analysis. Four publications were follow-up
publications on identical cases or case series and therefore
excluded from analysis.
Figure 1. Flow chart of search and selection of eligible publications.
doi:10.1371/journal.pntd.0001154.g001
Author Summary
The risk of anaphylactic shock is the objection most often
raised by opponents of percutaneous treatments for cystic
echinococcosis, but there are no updated figures on the
actual occurrence of anaphylaxis as a complication of this
treatment.
To assess the number of lethal and non-lethal anaphylactic
reactions following percutaneous aspiration of echinococcal
cysts, we systematically reviewed the literature published
from 1980–2010.
The analysis of the available literature shows that the risk
of severe anaphylactic reactions resulting from percutane-
ous treatment of echinococcal cysts has been widely
exaggerated and the actual risk may be lower than that
following administration of certain antibiotics.
Provided adequate stand-by resuscitation measures are
available, each time an echinococcal cyst is punctured, fear
of anaphylactic shock is no longer justified as an argument
to avoid this therapeutic option.
Anaphylaxis and Treatment of Cystic Echinococcosis
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In all but three of the publications included, detailed
information about the observed reversible complications were
available. In one additional publication, the observed complica-
tions were specified but not quantified. These four publications
were labeled in the tables accordingly (Tables S1, S3, 5, 6, 7).
For 863 cysts, information concerning the organ location
involved was available, but exact number of cysts for each organ
was not. For 17 cysts, information about the location was not
available. The publications covering these 880 cysts were labeled
in the tables accordingly (Table 1).
A detailed analysis of the observed complications in reference to
size, stage, and exact location within the affected organs was
impossible due to lack of details in the original publications.
Overall, five lethal and 777 reversible complications were collected
(Tables 2, 6). Of the five lethal complications, three were related to
the PT procedure, while two fatalities occurred due to PT
‘‘unrelated causes’’. Of the three PT related fatalities, two lethal
anaphylactic shocks and one fatality ‘‘associated with the use of the
method’’ were reported. Unfortunately, detailed information
about the two fatalities due to ‘‘unrelated causes’’ [25,26] and
the fatality reported as ‘‘associated with the use of the method’’
[27] were not obtainable.
There were five fatal cases reported in 5943 performed PT
procedures. This occurred while treating 5517 echinococcal cysts
resulting in an overall fatality rate of 0.08% (5 in 5943) and 0.09%
(5 in 5517) respectively (Table 2). The overall fatality rate due to
lethal anaphylaxis is 0.03% (2 in 5943) and 0.04% (2 in 5517)
respectively (Table 2).
Reversible complications were reported in 345 out of 3440 PT
procedures (10%) for the treatment of 3232 liver echinococcal
cysts (Table 3), in nine out of 175 PT procedures (5%) for the
treatment of 142 extra-hepatic echinococcal cysts (Table 5) and in
423 out of 2328 PT procedures (18%) for the treatment of 2143
echinococcal cysts of unspecified anatomical location (Table 4).
In summary, 777 reversible complications were observed in
5943 PT procedures for the treatment of 5517 echinococcal cysts.
Therefore, reversible complications were observed in 13% of all
PT procedures, corresponding to 14% of all treated echinococcal
cysts (Table 6).
The reversible complications fall into three categories: anaphy-
lactic, potentially anaphylactic, and non-anaphylactic:
In total, 99 reversible anaphylactic reactions were reported in
5943 PT procedures for the treatment of 5517 echinococcal cysts.
Therefore, reversible allergic reactions complicated 1.7% of all PT
procedures, corresponding to 1.8% of all treated echinococcal
cysts (Table 7).
The potentially anaphylactic complications include ‘‘fever’’,
‘‘hypotensive reaction’’, ‘‘vaso-vagal-reaction’’, and ‘‘nausea and
vomiting’’. In total, 128 potentially anaphylactic reactions were
reported during 5943 PT procedures (2.1%) for the treatment of
5517 (2.3%) echinococcal cysts (Table 6).
Non-anaphylactic complications – ranging from frequently
observed ‘‘biliary fistulas’’ to very rare events such as ‘‘active arterial
hemorrhage’’, ‘‘intracystic bleeding’’ or ‘‘gallbladder hemorrhage’’ –
were reported in 550 cases during 5943 PT procedures (9.3%) for the
treatment of 5517 (10%) echinococcal cysts.
Discussion
Allergic reactions and anaphylaxis are IgE-mediated immediate
hypersensitivity reactions that occur when antigen-specific IgE,
Table 1. Percutaneous treatment of hydatid cysts of various locations.
Authors
Year of
publication Journal
No. of percutane-
ous treated cysts
in various locations
No. of percutaneous
treated liver cysts
No. of puncture
procedures
No. of
reversible
complications
No. of lethal
complications
Gargouri et al. 1990 Cardiovasc Intervent
Radiol.
120 * 120 7
Wang et al. 1994 Zhongguo Ji Sheng
Chong Xue Yu Ji
Sheng Chong Bing
Za Zhi
361 { 361 1
Saenz-Santamaria 1995 Diagn Cytopathol 17 { 17
Von Sinner et al. 1995 Acta Radiol 31 1 41 6
Vuitton et al. 2002 GUT 351 # 1263 1789 409
Total 880 1263 2328 423 0
*‘‘liver, peritoneum, spleen, kidney, muscle and bone’’.
{hepatic and abdominal hydatid cysts.
{no location specified.
1‘‘abdomen, thorax, spine and bone’’.
#abdominal hydatid cysts and ‘‘other locations’’.
doi:10.1371/journal.pntd.0001154.t001
Table 2. Overall lethal complications due to percutaneous
treatment of hydatid cysts.
Lethal complications
No. of
cases
% of
treated
hydatid
cysts
(n=5517)
% of
percutaneous
treatment
procedures
(n=5943)
Lethal anaphylactic shock * 2 0.04 0.03
Lethality related to
percutaneous treatment procedure {
1 0.02 0.02
Lethality not related to
percutaneous treatment procedure {
2 0.04 0.03
Total 5 0.09 0.08
*(Men et al.,1999; Giorgio et al., 2009).
{(Vishnevskii et al., 1992).
{(Khuroo et al., 1991; Gavrilin et al., 2002).
doi:10.1371/journal.pntd.0001154.t002
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bound to Fc receptors on mast cells and basophils, are cross linked
by the antigen, activating the cells to rapidly release a variety of
mediators such as histamine, enzymes and lipid mediators [28].
While anaphylactic reactions and allergic symptoms are usually
observed in cases of treatment-related rupture of echinococcal
cysts, they may also occur spontaneously. The symptoms vary
from mild urticaria to anaphylactic shock [29]. The presence of
specific IgE in serum of patients is a well known feature of CE with
levels varying according to cyst number, location, morphology,
disease severity, and cyst stage [30,31].
Despite 75% of CE patients having detectable levels of specific
IgE and histamine release by circulating basophils in response to
E. granulosus, antigens can be detected in 100% of patients [32].
Consequently, allergic reactions are rare and unpredictable. So
far, the predictive value of IgE titers (or of IgG4 titers, considered
‘‘anti-anaphylactic’’ isotypes) for the development of allergic
reactions has not been investigated.
Echinococcus allergens have mainly been studied with the aim of
improving the performance of diagnostic tests. Three conserved
proteins have been identified (EgEF-1b/d, EA21 and Eg2HSP70),
by screening of an E. granulosus cDNA library with IgE from
patients with and without cutaneous allergic manifestations
showing significantly different IgE-binding reactivity between
groups [33,34,35]. Nevertheless, the identification of such
reactivity by a patient’s IgE as a predictive factor for the
development of anaphylaxis has never been investigated. Another
appealing, still unexplored possibility, is the use of these allergens
for desensitization therapy. The control of CE-related allergic
reactions relies on the administration of vasoactive agents (e.g.
epinephrine) and corticosteroids. Although a study reported less
severe hemodynamic alterations in surgical patients pre-treated
with histamine H1 plus H2 receptor blockers [36], the usefulness
of any pre-operative treatment for the prevention of anaphylaxis
has never been demonstrated.
The pathogenesis of anaphylactic reactions in CE is still unclear
but commonly explained by the disruption of the integrity of the
cyst wall with spillage and translocation of allergenic cyst contents
into the host’s circulation. Despite this, rupture of echinococcal
cysts does not always or necessarily lead to anaphylactic reactions.
In a series of 24 patients with proven rupture of echinococcal cysts
(12 patients with liver cysts and 12 patients with lung cysts) only
four patients (16.7%) had symptoms or a history of allergic
reactions [37]. The same observation has been made during
surgery of echinococcal cysts, were apparent spillage of cyst fluid –
despite all precautions taken – is reported to occur in 5% to 10%
of cases, without this necessarily leading to anaphylaxis [38].
In our review, we found an incidence of three anaphylactic
fatalities per 10,000 PT procedures (0.03%). To put this figure in
perspective, one may consider other conditions where treatment
entails the risks of lethal anaphylaxis:
N In the literature, fatal drug reactions are reported to occur in
0.1% of medical inpatients and 0.01% of surgical inpatients
(the main drugs implicated are antibiotics and non-steroidal
anti-inflammatory drugs) [39].
N Among drug-related allergic reactions, penicillin is one of the
drugs about which an abundance of data is available: the rate
of serious anaphylactic reactions among patients treated with
Table 3. Reversible complications due to percutaneous
treatment of hydatid liver cysts.
Reversible complications
No. of
cases
% of
treated
liver
hydatid
cysts
(n =3232)
% of
percutaneous
treatment
procedures
(n =3440)
Reversible severe anaphylactic reaction 4 0.12 0.12
Reversible mild anaphylactic reaction 2 0.06 0.06
Reversible anaphylactic reaction not
specified
10 0.31 0.29
Allergic skin reaction (urticaria, rash,
pruritus)
65 2.01 1.89
Fever 98 3.03 2.85
Hypotensive reaction 14 0.43 0.41
Vaso-vagal reaction 1 0.03 0.03
Nausea & vomiting 1 0.03 0.03
Cavity infection/abscess 59 1.83 1.72
Biliary fistula/rupture 35 1.08 1.02
Persisting drainage * 2 0.06 0.06
Peritoneal leakage 2 0.06 0.06
Subcapsular haematoma 6 0.19 0.17
Intracystic bleeding 1 0.03 0.03
Gallbladder haemorrhage 1 0.03 0.03
Active arterial haemorrhage { 1 0.03 0.03
Right-sided pleural effusion 13 0.40 0.38
Right-sided pneumothorax 1 0.03 0.03
Transient hypernatraemia { 2 0.06 0.06
Non-classified reversible complication 27 0.84 0.78
Total 345 10.66 10.05
*‘‘Persisting drainage of serous fluid … was treated by keeping the drainage
catheter in place until cessation of drainage (range 2–30 d) (Men et al., 1999).
{Parenchymal liver laceration with active arterial haemorrhage from a branch of
the right hepatic artery and the need for endovascular and surgical
intervention (Loutfi et al., 2008).
{Due to the usage of hypertonic saline as scolecidal agent (Haddad et al., 2000).
doi:10.1371/journal.pntd.0001154.t003
Table 4. Reversible complications due to percutaneous
treatment of hydatid cysts of various locations.
Reversible complications
No. of
cases
% of
treated
hydatid
cysts
(n =2143)
% of
percutaneous
treatment
procedures
(n =2328)
Reversible moderate anaphylactic
reaction
7 0.33 0.30
Reversible minor allergic reactions 5 0.23 0.21
Reversible anaphylactic reactions { 4 0.19 0.17
Reversible anaphylactic reactions { 1 0.05 0.04
Hypotensive reaction 1 1 0.05 0.04
Fever 13 0.61 0.56
Bile leakage 392 18.29 16.84
Total 423 19.75 18.16
*published data is not specifying complications according to cyst location.
{‘‘facial oedema & acute dyspnoea’’ (Vuitton et al., 2002).
{unclassified reversible anaphylactic reaction (Wang et al., 1994).
1(Von Sinner et al. 1995).
doi:10.1371/journal.pntd.0001154.t004
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penicillin ranges from one to four per 10,000 treatment courses
[40,41].
N In a prospective international study to determine the incidence
of allergic reactions to monthly intramuscular benzathine
penicillin (penicillin G benzathine) injections for the preven-
tion of recurrences of rheumatic fever, 1790 patients from 11
countries were enrolled: 57 of the 1570 patients (3.2%) had an
allergic reaction, four (0.2%) had anaphylactic shock and one
patient had lethal anaphylaxis (0.05%)[42].
N Allergic reactions to radiographic contrast media are reported
to occur in 1% and death in 0.001 - 0.009% of patients [39].
Overall, we found a frequency of 1.67 reversible anaphylactic
reactions per 100 PT procedures of echinococcal cysts (1.67%)
(Table 7). The majority of these reversible anaphylactic reactions
were allergic skin reactions (urticaria, rash, pruritus), reported in
1.1 per 100 PT procedures (1.1%) (Table 7).
Again, to put these figures in perspective, we consulted the
literature on drug-related allergic skin reactions: in a large
surveillance program on drug-induced allergic cutaneous reactions
– including 15,238 consecutive inpatients – Bigby et al. found
antibiotics to be associated with the highest risk. Among the 51
drugs studied, allergic cutaneous reactions were observed in 1.8%
to 5% of all treated patients (penicillin G: 1.8%, erythromycin:
2%, semisynthetic penicillins: 2.1%, cephalosporins: 2.1%,
ampicillin: 3.3%, trimethoprim-sulfamethoxazole: 3.4%, amoxi-
cillin: 5%). In the same study, 2.2% of patients receiving blood
products presented allergic cutaneous reactions [43].
One problem with allergic reactions from the puncture or
surgery of echinococcal cysts is that the exact pathophysiological
cause and correlation with consecutive symptoms remains unclear.
Some peri-interventional complications reported as ‘‘fever’’ (111
cases), ‘‘hypotensive reaction’’ (15 cases), ‘‘vaso-vagal-reaction’’ (1
case), and ‘‘nausea and vomiting’’ (1 case) (Table 6) might
represent allergic reactions. If this were to be the case, the risk of
reversible allergic reactions might be as high as 3.8 per 100 PT
procedures (3.8%). Even though some of these cases might
represent anaphylactic reactions, it can be assumed that most of
the ‘‘fever’’ events (111 of the 128 potentially anaphylactic
reactions) are due to infections, as post-interventional ‘‘cavity
infections’’ and ‘‘abscesses’’ account for 60 of the total 550 non-
allergic reversible complications (Table 6).
Additionally, the concept of anaphylaxis awaits a stricter
definition, as there is no consensus on exactly how to define it
along with considerable disagreement about its prevalence,
diagnosis and management [44,45].
The retrospective evaluation of publications on PT related
complications is certainly limited by a number of factors such as
non-uniform definitions of anaphylactic events, the merging of
data from different kind of studies – covering different PT methods
in different settings and dealing with a different composition of
clinical cases – and the denominator issue. Due to the retrospective
nature of our review and because we can only analyze published
Table 5. Reversible complications due to percutaneous
treatment of extra-hepatic hydatid cysts.
Reversible complications
No. of
cases
% of treated
non-hepatic
hydatid cysts
(n =142)
% of
percutaneous
treatment
procedures of
non-hepatic
cysts (n =175)
Allergic skin reaction (urticaria) 1 0.70 0.57
‘‘Fever & urticaria’’ x * - -
Pneumothorax 1 { 0.70 0.57
Cavity infection/abscess 1 0.70 0.57
Non-classified reversible
complication
6 4.23 3.43
Total 9 6.33 5.14
*‘‘no complications were observed except…fever and urticaria’’, no figures
given (Zerem et al., 2005 [10 cases of percutaneous treated spleen hydatid
cysts]).
{Percutaneous treatment of a lung hydatid cyst (Gagal et al., 2005).
doi:10.1371/journal.pntd.0001154.t005
Table 6. Overall reversible complications due to
percutaneous treatment of hydatid cysts.
Reversible complications
No. of
cases
% of treated
hydatid cysts
(n =5517)
% of
percutaneous
treatment
procedures
(n =5943)
Reversible severe anaphylactic
reaction
4 0.07 0.07
Reversible moderate
anaphylactic reaction
7 0.13 0.12
Reversible mild/minor
anaphylactic reaction
7 0.13 0.12
Reversible anaphylactic
reaction not specified
15 0.27 0.25
Allergic skin reaction
(urticaria, rash, pruritus)
66 1.20 1.11
‘‘Fever & urticaria’’ x * - -
Hypotensive reaction 15 0.27 0.25
Fever 111 2.01 1.87
Vaso-vagal reaction 1 0.02 0.02
Nausea & vomiting 1 0.02 0.02
Cavity infection/abscess 60 1.09 1.01
Biliary fistula/leakage/rupture 427 7.74 7.18
Persisting drainage { 2 0.04 0.03
Peritoneal leakage 2 0.04 0.03
Subcapsular haematoma 6 0.11 0.10
Intracystic bleeding 1 0.02 0.02
Gallbladder haemorrhage 1 0.02 0.02
Active arterial haemorrhage { 1 0.02 0.02
Right-sided pleural effusion 13 0.24 0.22
Pneumothorax 2 0.04 0.03
Transient hypernatraemia 1 2 0.04 0.03
Non-classified reversible
complication
33 0.60 0.56
Total 777 14.12 13.08
*‘‘no complications were observed except…fever and urticaria’’, no figures
given (Zerem et al., 2005 [10 cases of percutaneous treated spleen hydatid
cysts]).
{‘‘Persisting drainage of serous fluid … was treated by keeping the drainage
catheter in place until cessation of drainage (range 2–30 d)’’ (Men et al., 1999).
{Parenchymal liver laceration with active arterial haemorrhage from a branch of
the right hepatic artery and the need for endovascular and surgical
intervention (Loutfi et al., 2008).
1Due to the usage of hypertonic saline as scolecidal agent (Haddad et al., 2000).
doi:10.1371/journal.pntd.0001154.t006
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data, a publication bias can also be at work. It can be argued that
severe events (e.g. severe anaphylaxis) might be more likely be be
published. But one could counter that events assumed to be
common (especially the often quoted PT related anaphylaxis)
might not as readily be published. Nevertheless, we consider the
analysis of the existing published literature a justified approach as
no other source of more accurate data is currently available.
Future work in this area is needed to investigate the
pathophysiology of anaphylactic reactions in CE and to prospec-
tively study the potential relationship between clinical variables
such as location, number, size, stage of the cyst, and risk of
anaphylactic reactions. While large, well-designed clinical trials are
needed to develop treatment algorithms stratified by cyst stage and
available level of health care resources, the analysis of the available
literature shows that the traditional fear of lethal anaphylaxis and
allergic reactions in PT of echinococcal cysts has been exaggerated
by the critics of PT. Provided adequate stand-by resuscitation
measures are available, each time an echinococcal cyst is
punctured, fear of anaphylactic shock is no longer justified as an
argument to avoid this therapeutic option.
A necessary evolution in the clinical management of CE will be
the comparative evaluation of different PT and surgical methods
in certain situations.
While surgery legitimately maintains a central role in compli-
cated cysts (rupture, biliary fistulas, compression of vital structures,
bacterial superinfection, haemorrhage), cysts at high risk of
rupture, or large cysts with many daughter vesicles, that are not
suitable for percutaneous treatment approaches, PT has shown to
be a safe and effective alternative for many patients with suitable
cysts. What is needed now are evidence-based criteria to allocate
the patient to the most appropriate treatment option according to
the specific situation.
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